| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Acth (4-10) targets melanocortin receptors, particularly the melanocortin 4 receptor (MC4-R). ACTH (4-10) is the core sequence of all melanocortins and exclusively binds to MC4-R. MC4-R is a G protein-coupled receptor that is widely expressed in the central nervous system and plays a critical role in the regulation of energy homeostasis, feeding behavior, and stress responses. By binding to and activating MC4-R, ACTH (4-10) modulates various physiological processes, including learning, memory, and stress responses.
|
|---|---|
| ln Vitro |
Adrenocorticotropic hormone (human) (ACTH (4-10), which exclusively binds to MC4-R, is the core sequence of all melanocortins. After six weeks of continuous treatment, ACTH (4–10) in humans enters the cerebral fluid compartment through intranasal administration and causes complete body fat reduction [1].
In vitro, ACTH (4-10) is a potent melanocortin receptor agonist. It has been shown to have an EC50 of 23 nM for MC3 and 330 nM for MC4 receptors. Its activity is typically measured using cell-based assays that assess receptor activation, such as cAMP accumulation assays in cells expressing melanocortin receptors. These in vitro studies confirm ACTH (4-10)'s activity as a melanocortin receptor agonist. |
| ln Vivo |
In vivo, ACTH (4-10) has been shown to facilitate active and passive avoidance acquisition, improve short-term memory consolidation, and promote memory retrieval. After six weeks of continuous treatment, ACTH (4-10) in humans enters the cerebral fluid compartment through intranasal administration and causes complete body fat reduction. These in vivo studies confirm ACTH (4-10)'s effects on learning, memory, and metabolism.
|
| Enzyme Assay |
In vitro receptor binding assays for ACTH (4-10) measure its affinity for melanocortin receptors, particularly MC4-R. Membranes from cells expressing MC4-R are incubated with a radiolabeled MC4-R ligand and varying concentrations of ACTH (4-10). The Ki is determined from competition binding curves. Functional assays measure the activation of MC4-R-mediated signaling, such as the stimulation of cAMP accumulation. Cells expressing MC4-R are treated with ACTH (4-10), and the levels of cAMP are measured.
|
| Cell Assay |
In vitro cell-based assays for ACTH (4-10) are used to study its effects on melanocortin receptor signaling. Cells expressing MC4-R are treated with ACTH (4-10), and the accumulation of cAMP is measured. The EC50 is determined from the dose-response curve. These assays confirm the compound's agonist activity at the MC4-R.
|
| Animal Protocol |
In vivo animal experiments for ACTH (4-10) are conducted in animal models of learning, memory, and metabolism. In a typical study, ACTH (4-10) is administered to rodents, and its effects on learning and memory are assessed using behavioral tests such as the passive avoidance test or the Morris water maze. The compound's effects on metabolism are assessed by measuring body weight and fat mass. These studies confirm the in vivo activity of ACTH (4-10).
|
| ADME/Pharmacokinetics |
Acth (4-10) has a molecular weight of approximately 861.0 g/mol and a molecular formula of C40H56N14O9S. It has a CAS number of 4037-01-8. It is a solid peptide. It is soluble in water. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have been characterized. ACTH (4-10) can enter the cerebral fluid compartment through intranasal administration.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for ACTH (4-10) is not provided in standard product descriptions. As a peptide fragment of a naturally occurring hormone, it is generally considered to have low toxicity. However, as with all research chemicals, standard laboratory safety precautions should be followed when handling ACTH (4-10). Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
Acth (4-10) is a research compound and is not approved for any clinical or therapeutic use. It is a peptide fragment derived from adrenocorticotropic hormone (ACTH), consisting of seven amino acids. It is a water-soluble potent melanocortin receptor agonist. ACTH (4-10) is a melanocortin 4 receptor (MC4-R) agonist. It facilitates active and passive avoidance acquisition, improves short-term memory consolidation, and promotes memory retrieval. ACTH (4-10) is a valuable research tool for studying melanocortin receptor function, memory, and stress responses.
|
| Exact Mass |
961.422
|
|---|---|
| CAS # |
4037-01-8
|
| Related CAS # |
4037-01-8 4-10-Semax ACTH - msh (4-10); Adrenocorticotropic hormone 4-10 Met-glu-his-phe-arg-trp-gly Msh-acth (4-10);
|
| PubChem CID |
123787
|
| Appearance |
White to off-white solid powder
|
| Density |
1.48g/cm3
|
| Vapour Pressure |
4.64E-09mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
9.435
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
68
|
| Complexity |
1740
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CSCCC(N)C(NC(C(NC(C(NC(C(NC(C(NC(C(NCC(O)=O)=O)CC1=CNC2=CC=CC=C12)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)CC4=CN=CN4)=O)CCC(O)=O)=O
|
| InChi Key |
HAAUASBAIUJHAN-LXOXETEGSA-N
|
| InChi Code |
InChI=1S/C44H59N13O10S/c1-68-17-15-29(45)38(62)53-32(13-14-36(58)59)41(65)57-35(20-27-22-48-24-52-27)43(67)55-33(18-25-8-3-2-4-9-25)42(66)54-31(12-7-16-49-44(46)47)40(64)56-34(39(63)51-23-37(60)61)19-26-21-50-30-11-6-5-10-28(26)30/h2-6,8-11,21-22,24,29,31-35,50H,7,12-20,23,45H2,1H3,(H,48,52)(H,51,63)(H,53,62)(H,54,66)(H,55,67)(H,56,64)(H,57,65)(H,58,59)(H,60,61)(H4,46,47,49)/t29-,31-,32-,33-,34-,35-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| Synonyms |
Acth (4-10) Related CAS#
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~25.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02446886 | TERMINATEDWITH RESULTS | Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) | Multiple Sclerosis | Weill Medical College of Cornell University | 2016-06 | Phase 4 |
| NCT02132195 | COMPLETEDWITH RESULTS | Drug: ACTH | Nephrotic Syndrome | Emory University | 2014-05 | Phase 3 |
| NCT01028287 | COMPLETED | Drug: ACTH Drug: ACTH |
Diabetic Nephropathy Nephrotic Syndrome |
Southeast Renal Research Institute | 2009-05 | Phase 4 |
| NCT02030028 | COMPLETEDWITH RESULTS | Drug: ACTHAR gel | Rheumatoid Arthritis | Dana Ascherman | 2014-11 | Not Applicable |
| NCT02931175 | UNKNOWN STATUS | Drug: ACTH gel | Uveitis | Quan Dong Nguyen | 2017-01 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
